Researchers in Prof. Mark Kay's laboratory have developed recombinant adeno-associated viral (AAV) capsid proteins that transduce human primary hepatocytes at high efficiency in vitro and in vivo.
Researchers from Dr. Mark Kay's laboratory at Stanford University have merged desirable qualities of multiple natural AAV isolates by an adapted DNA family shuffling technology to create a complex library of hybrid capsids from eight different wild-type viruses.
Researchers in Prof. Mark Kay's laboratory have developed a robust vector that combines the ease of plasmid preparation with the stable expression achieved by minicircle vectors.
Researchers in Dr. Bingwei Lu's lab have identified genes that could serve as therapeutic targets for the treatment of Parkinson's disease (PD). PD is a common neurodegenerative movement disorder affecting 1% of the population over the age 60.
Stanford researchers have developed a highly specific, tunable system to improve the safety, efficacy and deliverability of gene therapy vectors and other biological therapies.
Researchers in Dr. Mark Kay's laboratory at Stanford University have designed a new liver-specific expression cassette for inserting genes into double-stranded AAV (adeno-associated virus) vectors for gene therapy.